This is a company with great potential and already it has accomplished much in the standardization of agricultural procedures for high quality pharmaceutical grade DAR.
Sichuan, PRC (PRWEB) November 30, 2010
China Health Resources Inc. announced today that Jiayin Wang, a prominent Chinese business leader and politician, is the new chief executive officer.
Wang had been CHRI's president and director for the past two years. He now replaces Jiang Chen, who served as CHRI’s CEO since 2006.
Wang has served as president and Chairman of the Board of Directors of Sichuan Yinfa Resource Development Co., Ltd., an affiliate of CHRI, where he spearheaded the development of the standardization of pharmaceutical grade for Dahurian Angelica Root (DAR) under the Chinese State Food and Drug Administration Good Agricultural Practice of Medical Plants and Animals. Additionally, Wang has been the People's Senator of Suining City, Sichuan Province and the People's Republic of China ("PRC") since 1995 and the Chairman of Sichuan Province DAR Association since 2001.
"I'm very pleased to take a more active role in CHRI,” said Wang. "This is a company with great potential and already it has accomplished much in the standardization of agricultural procedures for high quality pharmaceutical grade DAR. The CHRI team has done a tremendous job over the past year in restructuring the company and refocusing its approach to the business. I'm excited about the opportunity to lead CHRI and build on the momentum to grow the business by solidifying our DAR franchise and expanding beyond its borders and it product line."
In the restructuring of the executive management, Weihai Liu has been named chief financial officer.
Liu was finance manager in Guangdong Dongsong Sanxiong Electrical Appliance Co., Ltd where he was in charge of all aspects in budget management, accounting, financial management, taxation planning, assets and investment risk management. He also created systems of cost accounting, cost control, cost analysis, internal audit and also the financial management of all branch companies.
"Weihai Liu brings the right skill set to lead CHRI as CFO as we move from a focus on restructuring and stabilization to a focus on growth and profitability," said Wang. "Liu's financial and management skills and extensive experience in accounting, financial management and cost control make him the right CFO for CHRI at this important phase."
China Health Resource Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and related products in the People's Republic of China. DAR is a herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.
Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.
# # #